Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
March 13 2023 - 6:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT
TO SECTION 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March, 2023
Commission File Number: 001-36815
Ascendis Pharma A/S
(Exact Name of Registrant as Specified in Its Charter)
Tuborg
Boulevard 12
DK-2900 Hellerup
Denmark
(Address of
principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover
of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Ascendis Pharma A/S (the Company) is aware that the Federal Deposit Insurance Corporation (the
FDIC) has announced that Silicon Valley Bank (SVB) has been closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver. The Company does not hold deposits or securities or
maintain any accounts at SVB.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Ascendis Pharma A/S |
|
|
|
|
Date: March 13, 2023 |
|
|
|
By: |
|
/s/ Michael Wolff Jensen |
|
|
|
|
|
|
Michael Wolff Jensen |
|
|
|
|
|
|
Executive Vice President, Chief Legal Officer |
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Apr 2024 to May 2024
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From May 2023 to May 2024